Comment from Prime Plus, Inc.

Summary: Karen L. Giblin, President of Prime Plus, Inc., opposes the FDA's proposal to withdraw approval of three estrogen/androgen combination drugs. She argues that these drugs provide significant benefits for menopausal women, particularly those who have undergone surgical menopause, and contends that the patient population in need of such therapy is much larger than the FDA estimates.